Y-Intercept (Hong Kong) 13F: Exits AbbVie (ABBV) Stake

Y-Intercept (Hong Kong) has sold out of its position in AbbVie Inc. (NYSE: ABBV), reducing its holdings from 74,248 shares to zero in a filing on October 16, 2026. This sale reflects a complete exit from the investment, which at a recent price of $285.52 was valued at approximately $21.2 million.

What Changed in Y-Intercept's AbbVie Position

Y-Intercept's cut in its AbbVie holdings represents a 100.0% decrease, leaving the fund without any shares.

Other Institutional Activity in AbbVie

Several other funds have adjusted their positions in AbbVie. Blackrock Inc. reduced its holdings by 1,205,552 shares, totaling 149,488,412 shares worth about $42.7 billion. Vanguard Capital Management LLC raised its stake, adding 516,956 shares for a total of 115,396,098 shares valued at approximately $32.9 billion. Similarly, State Street Corporation grew its position by 1,380,673 shares, bringing its total to 82,596,748 shares valued at around $23.6 billion. In contrast, Vanguard Portfolio Management LLC decreased its holdings by 1,044,934 shares, ending with 48,477,996 shares worth about $13.8 billion. Lastly, JPMorgan Chase & Co. significantly cut its position, reducing shares by 8,880,294 to 47,862,796 shares valued at about $13.7 billion.

AbbVie Inc. Stock Up 0.7%

AbbVie shares recently traded at $285.52, which is above both its 50-day moving average by 9.1% and its 200-day moving average by 22.2%. However, the stock is slightly below its 52-week high of $291.40 by 2.0% and is significantly above its 52-week low of $190.75 by 49.7%. The stock's current price is also above the mean price target of $282.61 set by analysts.

Recent Earnings

For its latest earnings report, AbbVie announced revenue of approximately $64.4 billion for the trailing twelve months, reflecting a yearly growth of 10.2%. The company's earnings per share (EPS) stood at $3.54, and it boasts a net margin of 9.8%. AbbVie's next earnings call is scheduled for October 30, 2026.

Insider Buying and Selling at AbbVie Inc.

Insider trading activity has shown several sales recently. Perry C. Siatis, General Counsel, sold 22,381 shares at an average price of $230.00, totaling approximately $5.1 million on February 25, 2026. He also sold 18,668 shares on March 2, 2026, valued at around $4.4 million. Another officer, David Ryan Purdue, sold 5,230 shares at $233.56, totaling about $1.2 million on March 4, 2026. Nicholas Donoghoe, also an officer, sold 32,710 shares at an average price of $250.00, valued at about $8.2 million on August 14, 2026.

Analysts Set New Price Targets

Analysts have been generally optimistic about AbbVie. On October 8, 2026, JP Morgan maintained its 'Overweight' rating with a target price of $300.00, up from a previous target of $285.00. Cantor Fitzgerald also maintained its 'Overweight' rating, with a similar increase in the target to $290.00. UBS, however, kept a 'Neutral' rating but raised its target from $260.00 to $275.00. Guggenheim reiterated a 'Buy' rating with a target of $288.00 on October 9, while RBC Capital maintained its 'Outperform' rating with a target of $280.00 on October 13.

About AbbVie

AbbVie Inc., headquartered in North Chicago, IL, is a biopharmaceutical company that researches, develops, and sells medicines globally. The company's portfolio includes treatments for autoimmune diseases, blood cancers, and other serious conditions. AbbVie's recent stock activity may reflect broader trends in healthcare investments and shifting institutional interests.

Bottom Line

Y-Intercept's complete exit from AbbVie could indicate a strategic shift in its portfolio management. With AbbVie set to report its next earnings on October 30, investors will be looking for performance insights that might influence future positions. This filing reflects holdings as of the reporting period and may not represent Y-Intercept's current position. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.